A hallmark of our laboratory is the development of novel and innovative in vivo tumor models that allow us to study barriers in the delivery of therapeutic agents. This is only possible because of the outstanding surgical expertise and unique animal facility available in the Steele Laboratory since its inception in 1975. This Core will continue to serve two major functions: (i) the surgical support, including novel animal model development, and (ii) the breeding and maintenance of mice, including genetically engineered mice (GEM). Both are vital for successful completion of all Program Project Grant (PPG) goals. Thus, Core C is a cornerstone of this PPG. This Core will continue to develop or improve and provide sophisticated orthotopic tumor models - syngeneic tumor grafts (all four Projects) - as well as cranial window (Projects 1), lung window (Project 2), liver tumor preparation (Project 2, 3) and abdominal window (Project 4). These will enable in vivo time-course monitoring of molecular, cellular, anatomical, and functional parameters in the orthotopic organ environment of brain, colon, liver and pancreatic tumors and their metastases. In addition, this Core will significantly expand maintenance and provision of GEM models in this revised PPG in order to meet a surge of GEM demand from all 4 Projects to study the role of the host microenvironment in response to treatment in spontaneous tumors. Through his leadership of the operation of Cox-7 gnotobiotic animal facility. Dr. Huang will continue to ensure that all experimental animals are of uniform quality and free of murine viruses, pathogenic bacteria, and parasites. This will enable the PPG team to carry out all experimental procedures without the use of antibiotics. These studies are extremely difficult and more costly elsewhere. Currently 26 defined-flora genetically engineered mouse lines are available in the Cox-7 facility. Based on the need of all 4 Projects, additional mouse lines will also be engineered or rederived, bred, and produced within the facility. Tumors that are screened and free of mouse pathogens will be serially passaged in vivo and implanted into experimental animals within the colony. In vivo tumors will not be passaged beyond the fifth generation (F5) to avoid changes in tumor characteristics. This assures tight control of the quality of animals and tumors. Core C will continue to provide standard animal procedures such as controlled-release pump implantation, vascular line placement, post-surgical care and tissue collection.

Public Health Relevance

The overall goal of the proposed Program Project Grant is to develop strategies to overcome barriers to effective treatment of brain, colorectal, liver and pancreatic cancers. Preclinical models, which resemble the clinical features of these tumors, are absolutely essential. This core continues to provide outstanding surgical expertise and high quality and quantity of genetically engineered mice to all four Projects. Thus, Core C forms a cornerstone of this Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA080124-11A1
Application #
8299770
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (J1))
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
11
Fiscal Year
2012
Total Cost
$437,672
Indirect Cost
$186,737
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Ramjiawan, Rakesh R; Griffioen, Arjan W; Duda, Dan G (2017) Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis 20:185-204
Jung, Keehoon; Heishi, Takahiro; Khan, Omar F et al. (2017) Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest 127:3039-3051
Chen, Yunching; Liu, Ya-Chi; Sung, Yun-Chieh et al. (2017) Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep 7:44123
Aoki, Shuichi; Cobbold, Mark; Zhu, Andrew X et al. (2017) Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Hepatology :
Mitchell, Michael J; Jain, Rakesh K; Langer, Robert (2017) Engineering and physical sciences in oncology: challenges and opportunities. Nat Rev Cancer 17:659-675
Kalpathy-Cramer, Jayashree; Chandra, Vyshak; Da, Xiao et al. (2017) Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol 131:603-610
Menter, Alex R; Carroll, Nikki M; Sakoda, Lori C et al. (2017) Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer 18:189-197.e3
Li, Suyan; Kumar T, Peeyush; Joshee, Sampada et al. (2017) Endothelial cell-derived GABA signaling modulates neuronal migration and postnatal behavior. Cell Res :
Naxerova, Kamila; Reiter, Johannes G; Brachtel, Elena et al. (2017) Origins of lymphatic and distant metastases in human colorectal cancer. Science 357:55-60
Rowlands, Christopher J; Park, Demian; Bruns, Oliver T et al. (2017) Wide-field three-photon excitation in biological samples. Light Sci Appl 6:e16255

Showing the most recent 10 out of 271 publications